In the CC Q&A, Rick Gonzalez (CEO) said the end-2015 V-Pak run rate will be close to the original guidance and might still hit the guidance, but his best guess is that they will come in a little short.
Gonzalez also emphasized that ABBV's 2016 HCV sales will be larger than 2015 as V-Pak is launched in Japan and additional EU countries.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.